Thorsten Ruf
Roche (Switzerland) · 29 works · 1,682 citations · h-index 10
Top works
- Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study
- Existence of the Frank-Starling Mechanism in the Failing Human Heart
- Alectinib in Resected ALK -Positive Non–Small-Cell Lung Cancer
- LBA2 ALINA: Efficacy and safety of adjuvant alectinib versus chemotherapy in patients with early-stage ALK+ non-small cell lung cancer (NSCLC)
- Effect of alectinib on cardiac electrophysiology: results from intensive electrocardiogram monitoring from the pivotal phase II NP28761 and NP28673 studies
- Positive and Negative Inotropic Effects of dl -Sotalol and d -Sotalol in Failing and Nonfailing Human Myocardium Under Physiological Experimental Conditions
- Alterations of cross-bridge kinetics in human atrial and ventricular myocardium
- Clinical experience and management of adverse events in patients with advanced ALK-positive non-small-cell lung cancer receiving alectinib
- Final efficacy and safety data, and exploratory molecular profiling from the phase III ALUR study of alectinib versus chemotherapy in crizotinib-pretreated ALK-positive non-small-cell lung cancer
- Updated overall survival (OS) and safety data from the randomized, phase III ALEX study of alectinib (ALC) versus crizotinib (CRZ) in untreated advanced ALK+ NSCLC.
- Lack of Pharmacokinetic Drug-Drug Interaction between Orlistat and Cerivastatin
- OA02.07 Phase 3 ALUR Study of Alectinib in Pretreated ALK+ NSCLC: Final Efficacy, Safety and Targeted Genomic Sequencing Analyses
- Exposure‐Response Relationships for Pralsetinib in Patients with RET‐Altered Thyroid Cancer or RET Fusion‐Positive Nonsmall Cell Lung Cancer
- Optimized Alectinib Dose Regimen for Treatment of Patients With ALK‐Positive Non‐Small Cell Lung Cancer Based on Robust Pharmacometric Analyses and Clinical Evidence
- Modulation of myocardial economy and efficiency in mammalian failing and non-failing myocardium by calcium channel activation and β-adrenergic stimulation
- Metabolism, Excretion, and Pharmacokinetics of [14C]-Radiolabeled Aleglitazar: A Phase I, Nonrandomized, Open-Label, Single-Center, Single-Dose Study in Healthy Male Volunteers
- Health-related quality of life (HRQoL) results for adjuvant alectinib vs chemotherapy in patients with resected ALK+ non-small cell lung cancer (NSCLC): Data from ALINA.
- OA13.04 ALINA Safety Results: Adjuvant Alectinib vs Chemotherapy in Patients with Resected ALK+ Non-Small Cell Lung Cancer (NSCLC)
- No Evidence of QT Prolongation With Supratherapeutic Doses of Aleglitazar
- Abstract CT039: Alectinib in children and adolescents with solid or CNS tumors harboring ALK-fusions: Data from the iMATRIX Alectinib Phase I/II open-label, multi-center study